Dementia Drugs Market by Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia), Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors) - Global Forecast 2024-2030

Dementia Drugs Market by Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia), Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors) - Global Forecast 2024-2030


The Dementia Drugs Market size was estimated at USD 9.80 billion in 2023 and expected to reach USD 10.78 billion in 2024, at a CAGR 10.39% to reach USD 19.58 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Dementia Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Dementia Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Dementia Drugs Market, highlighting leading vendors and their innovative profiles. These include Anavex Life Sciences Corp., AstraZeneca PLC, Aurobindo Pharma Limited, Biogen Inc., Eisai Co., Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., Janssen Global Services, LLC, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Quidel Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Dementia Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Indications
Alzheimer's Disease

Lewy Body Dementia

Parkinsons Disease Dementia

Vascular Dementia
Drug Class
Cholinesterase Inhibitors

Glutamate Inhibitors

MAO Inhibitors
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Dementia Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Dementia Drugs Market?
3. What are the technology trends and regulatory frameworks in the Dementia Drugs Market?
4. What is the market share of the leading vendors in the Dementia Drugs Market?
5. Which modes and strategic moves are suitable for entering the Dementia Drugs Market?PDF E-mail From Publisher (2-5)Users License


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Dementia Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing geriatric population base
5.1.1.2. Increase in prevalence of Alzheimer disease
5.1.1.3. Government funding & awareness programs for Alzheimer disease
5.1.2. Restraints
5.1.2.1. High costs of research and drug development
5.1.3. Opportunities
5.1.3.1. Continuous growth in popularity of online pharmacy services due to providing safe and reliable access to medication
5.1.3.2. Advancement of new drugs and treatments
5.1.3.3. Advancing therapeutic and biomarker development for Alzheimer's and related dementias created funding opportunities
5.1.4. Challenges
5.1.4.1. Complex pathology and etiology and no biomarkers for early detection of the disease
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Dementia Drugs Market, by Indications
6.1. Introduction
6.2. Alzheimer's Disease
6.3. Lewy Body Dementia
6.4. Parkinsons Disease Dementia
6.5. Vascular Dementia
7. Dementia Drugs Market, by Drug Class
7.1. Introduction
7.2. Cholinesterase Inhibitors
7.3. Glutamate Inhibitors
7.4. MAO Inhibitors
8. Americas Dementia Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Dementia Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Dementia Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Anavex Life Sciences Corp.
12.1.2. AstraZeneca PLC
12.1.3. Aurobindo Pharma Limited
12.1.4. Biogen Inc.
12.1.5. Eisai Co., Ltd
12.1.6. Eli Lilly and Company
12.1.7. F. Hoffmann-La Roche AG
12.1.8. Forest Laboratories, Inc.
12.1.9. Janssen Global Services, LLC
12.1.10. Merck & Co., Inc.
12.1.11. Novartis AG
12.1.12. Pfizer, Inc.
12.1.13. Quidel Corporation
12.1.14. Sanofi S.A.
12.1.15. Teva Pharmaceutical Industries Ltd.
12.1.16. Valeant Pharmaceuticals International, Inc.
12.1.17. Zydus Cadila
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. DEMENTIA DRUGS MARKET RESEARCH PROCESS
FIGURE 2. DEMENTIA DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. DEMENTIA DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. DEMENTIA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. DEMENTIA DRUGS MARKET DYNAMICS
FIGURE 7. DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2030 (%)
FIGURE 8. DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings